| 查看: 398 | 回复: 0 | |||
[交流]
3-13岁变应性鼻炎患儿舌下特异性免疫治疗的疗效和安全性评估
|
|
Background: Sublingual immunotherapy (SLIT) is recommended for allergic diseases. However, clinical studies containing evidence-based data of thistreatment in young children, which is rarely reported in the literature, are needed. This study was designed to assess the efficacy and safety of SLIT in children,including very young children. Methods: Two hundred sixty-four children aged 3–13 years old (133 children, 3–5 years old) with Dermatophagoides farinae–induced allergic rhinitiswith or without asthma treated by standard harmacotherapy had randomly received either SLIT (SLIT group) or no SLIT (control group) for 12 months. Symptoms, medications, visual analog scale (VAS) and presence of adverse events (AEs) were assessed at monthly visits. Skin-prick test and Dermatophagoides farinae-specific IgE and IgG4 were easured before and after treatment. Results: Both treatments were effective in the global clinical scores during the first seven visits when compared with baseline (all, p 0.01), and SLIT showed lower symptoms scores and VAS scores throughout this period (all, p 0.01). These improvements continued until the later visits only in the SLIT group. Also, the asthma medication consumption was decreased by SLIT treatment only at the end of study (p 0.01). The specific IgG4 was significantly increased after SLIT treatment when compared with the control group, but no significant change of specific IgE was observed in either groups. In the SLIT group, there was no significant difference between children less than or more than 5 years old in terms of clinical efficacy, onset of action, immunologic parameters, and safety. No severe systemic AEs were reported. Conclusion: SLIT is effective and well-tolerated in children with allergic rhinitis 3-13 years old. |
» 猜你喜欢
祈求今年青基拿下!
已经有13人回复
求genemapper软件
已经有0人回复
循环系统论文润色/翻译怎么收费?
已经有71人回复
耐心等待
已经有16人回复
求助
已经有2人回复
首都医科大学吴燕课题组2025年招收硕士研究生
已经有0人回复
Hoxd9基因在骨骼医学
已经有0人回复
考博求助
已经有3人回复
文献求助,急急急!!!!
已经有2人回复














回复此楼